Ethylmalonate

Ethylmalonate

SCHEMBL21269262

CCC(C(=O)[O-])C(=O)[O-].[Li+].[Na+]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Ethylmalonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
TSHR P16473 2/20 0.46
NFKB1 P19838 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CA2 P00918 4/20 0.44
CA1 P00915 5/20 0.39
FFAR3 O14843 2/20 0.39
HDAC3 O15379 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
CA4 P22748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylmalonate SCHEMBL108809 0.97 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL108038 0.97 CYP3A4 (0.48) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL21269202 0.94 CYP3A4 (0.46) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL21269251 0.94 CYP3A4 (0.42) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL106692 0.94 CYP3A4 (0.46) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL108552 0.94 CYP3A4 (0.42) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL21269702 0.91 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL9118939 0.91 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL8330729 0.91 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2
Ethylmalonate SCHEMBL9765249 0.91 CYP3A4 (0.43) CYP3A4TSHRNFKB1NPSR1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION LIMITED (IN) 2019-08-22 US claimed
EP-3527616-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION Ltd. (IN) 2019-08-21 EP claimed
EP-3527616-B1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORP LTD (IN) 2024-02-07 EP disclosed
US-11180630-B2 Metal salts of malonic acid as nucleating additives for crystalline thermoplastics INDIAN OIL CORPORATION LIMITED (IN) 2021-11-23 US disclosed
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION LIMITED (IN) 2019-08-22 US disclosed
EP-3527616-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS INDIAN OIL CORPORATION Ltd. (IN) 2019-08-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256683-A1 METAL SALTS OF MALONIC ACID AS NUCLEATING ADDITIVES FOR CRYSTALLINE THERMOPLASTICS NUMA1, MNS1, ME1 CYP3A4 3906/4885TSHR 4737/4885NFKB1 275/4885
US-11180630-B2 Metal salts of malonic acid as nucleating additives for crystalline thermoplastics NUMA1, MNS1, ME1 CYP3A4 3906/4885TSHR 4737/4885NFKB1 275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.